Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dell Technologies Inc (DELL) vs Moderna, Inc. (MRNA) Price & Performance

Dell Technologies IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Dell Technologies Inc vs Moderna, Inc. — how do they compare? Dell Technologies Inc trades at $481.2 (market cap $284.93B), while Moderna, Inc. trades at $63.65 (market cap $24.18B). The key difference: Dell Technologies Inc is far larger — about 11.8× Moderna, Inc.'s market cap, and Dell Technologies Inc pays a 0.57% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

DELLMRNA
Market Cap
$284.93B$24.18B
Sector
TechnologyHealth
52-Week High
$467.27$81.80
52-Week Low
$111.10$22.36
Enterprise Value
$304.51B$20.33B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dell Technologies Inc

Dell Technologies stock trades at $478.30, up 4.45% in the last session, reflecting strong momentum amid AI-driven server demand. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $4.86 surpassing the $2.96 forecast. The technical outlook is bullish, with the price above key moving averages, while fundamentals show revenue growth to $95.57 billion in 2025 and a net income margin of 6.28%.

The outlook remains positive given robust analyst sentiment, with a consensus price target of $503.76 implying upside. Key risks include valuation concerns at a P/E of 35.14 and potential margin pressure from memory shortages. Continued execution on AI server backlog and commercial PC refresh cycles are critical for sustained growth.

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dell Technologies Inc

VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses

Read more on DELL

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA